(RTTNews) - Achilles Therapeutics plc (ACHL) Thursday announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials.
American depositary receipts of Achilles Therapeutics rose 32% after the company disclosed cost-cutting measures as part of a strategic update. ADRs were trading around 94 cents. ADRs are up about 12% ...
As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents. The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and ...